ObesityNCT02405806
Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms
A study testing low carbohydrate food and standard food in people with Obesity and Diet Modification, run by Region Skane.
Trial summary
The overall aim for this study is to evaluate the clinical effects of a modified diet on metabolic risk factors such as diabetes mellitus and obesity, and the mechanisms this nutrition composition exerts on gastrointestinal physiology, inflammatory responses, and quality of life, where the subjects are their own… Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity, Diet Modification
- What is being tested?
- low carbohydrate food and standard food
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Nov 2014to 31 Dec 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy subjects should be healthy.
- Prediabetes should have fasting plasma glucose levels o 5.6-6.9 mmol/l or plasma glucose level 2 h after an oral glucose test of 7.8-11.1 mmol/l, without any diabetes treatment.
- Patients with diabetes should have type-2 diabetes.
- Obesity should have BMI 30-3 and glucose levels within reference values
Who cannot join
- Patients with diabetes or obesity should not have severe cardiac, kidney, liver or psychiatric diseases
About this study
The overall aim for this study is to evaluate the clinical effects of a modified diet on metabolic risk factors such as diabetes mellitus and obesity, and the mechanisms this nutrition composition exerts on gastrointestinal physiology, inflammatory responses, and quality of life, where the subjects are their own controls.
Within this study, the investigators will be able to relate the nutritional composition to metabolic disorders, the gut microbiota, secreted intestinal neuropeptides, and bio- and inflammatory markers in serum, plasma and urine.
Read the detailed description
Material and Methods
Subjects are recruited consequently from the primary care, and from the Department of Endocrinology.
Study population
The investigator will include:
- patients with type 2 diabetes to study the effect of a modified diet for 3 months;
- healthy volunteers for intake of two different breakfasts with some days in between the meals.
All categories will be exposed to exactly the same study design.
Protocols:
Various protocols will be used in the study, to collect information about the status at inclusion, and to be able to measure changes in anthropometry, health status and symptoms during the study period.
Study-questionnaire:
This questionnaire is similar to the questionnaires used in the great population cohorts Malmö Diet and Cancer Study (MDCS, general population from Malmö, N = 28 000), and Malmö Offspring Study (MOS) (general population from Malmö, children and grandchildren to participants in MDCS, calculated to include 5000 participants, started 2013, supported by grants from VR). It is also used in a newly started endoscopy study where all consecutive patients performing a colonoscopy at the Department of Gastroenterology in Malmö will be included (calculated to include 2000 participants). The questionnaire contains questions about socioeconomic factors, life style factors (including diet, smoking, stuff use, alcohol habits, physical activity), medical health, drug consumption, heredity factors and gastrointestinal symptoms.
Nutrition questionnaire:
This questionnaire is used to get information about ordinary diet, energy intake, and so on. This basic information is used to plan the diet from Life Science Lab, so similar energy supply and breakfast are provided.
36-item Short-Form questionnaire (SF-36): This is a world-wide used instrument to evaluate quality of life. It has been used to measure quality of life in many various diseases, and norm value references are available. The instrument measures physical functioning, role functional-physical, bodily pain, general health, vitality, social functioning, role functioning-emotional, and mental health. These parameters are valuable to evaluate, to estimate the effects evoked in daily life, by a change in life style factors.
Anthropometric protocol:
This questionnaire is used to screen the study participants before inclusion, and to be able to exclude patients with already ongoing weight-reducing diet. In addition, it contains questions about BMI, body composition, and a basal physical examination.
Satiety scoring:
This protocol has been used in previous studies by the group, to estimate the degree of hunger/satiety before and after a standardized meal.
Nutrition:
All subjects will get the diet delivered free from charge from Life Science Lab (Lund University). Life Science Lab was founded 1998 as a leading medical and technical research for advanced cardiovascular and thoracic surgery sciences. Due to the importance of life style effects on the cardiovascular diseases and well-being, Life Science Lab also conducts life style-related science to reduce known risk factors for cardiovascular diseases. The main focus is to develop healthy nutrition in normal food formula by reforming the food-meal composition for everyone. The meal-diet consists of ordinary raws, but with minimal industrial processing. The food is based on traditional Nordic raws, e.g. whole grains, vegetables, leguminous, root crops, fat fish, birds, fruits, berries and nuts. At the same time, the amount of sugar, read meat, processed meat, and dairy products is limited. The diet has a good nutritional supply, but contains less calories than what is usually recommended (2000 kcal/day compared with 2400 kcal/day).
The meal is planned together with the kitchen of Life science Lab. Food composition, recipes, and instructions how to cook the food is delivered regularly from Life Science Lab for lunch and dinner. The breakfasts for the subjects are planned together with the PI and the nutritionist at Life Science Lab, but the subjects have to buy the food themselves. Three alternatives are suggested, depending on their ordinary breakfast ingested, described in the nutrition questionnaire.
Neuropeptides/inflammatory markers:
The neuropeptides, or their precursors, that will be studied in serum/plasma are peptides involved in regulation of satiety and digestion, e.g. cholecystokinin (CCK), gastrin, ghrelin, glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2), leptin, motilin, neurotensin, oxytocin, and peptide YY (PYY). To evaluate permeability defects in the intestinal mucosa, levels of zonulin and bacterial endotoxins, i.e. lipopolysaccharides, will be measured in plasma. Low-graded inflammation is reflected by high-sensitive C-reactive protein (CRP), plasminogen activator inhibitor type 1 (PAI-1), and factors involved in AGE will be analyzed. In addition, different cytokines, tracers, and routine analyses will be performed. Cooperation with laboratories in Denmark and Great Britain will be established.
Gut microbiota:
DNA extractions and Terminal Restriction Fragment Length Polymorphism (T-RFLP) and quantification of specific bacterial groups will be done by quantitative polymerase chain reaction (PCR) in accordance with the protocols the investigator has used and described earlier by the research group. As reference, a restricted number of samples will be analyzed with massively-parallel pyrosequencing of partial ribosomal ribonucleic acid (rRNA) ribosomal genes. The gut microbiota bacterial constitution (bacterial species) will be correlated to gastrointestinal symptoms and diseases, and changes in bio- and inflammatory markers.
Study Design
When a group of patients are recruited, the investigator will have an information meeting for the whole group. At that meeting, held by the PI, the subjects will receive medical information about metabolic diseases, and about nutrition and its effects on health and disease.
After this initial meeting, the subjects are handled individually. For overview, se flow-chart, last page. At inclusion, all subjects have to complete questionnaires and some examinations:
- Study-questionnaire containing questions about ordinary lifestyle factors, socioeconomic factors, health- and drug information, heredity, and gastrointestinal symptoms;
- Nutrition questionnaire containing information about ordinary food habits
- Quality of life questionnaire SF-36;
- Anthropometric protocol, including nutritional screening, completed by the investigator; and
- Eight tubes (SST- phenolsulfotransferase platelet survival time (PST)- and ethylenediaminetetraacetic acid (EDTA) tubes), à 6 ml, to collect serum, plasma and blood cells. Feces sampling for microbiota analyses. Urine sampling during the night. All biological material will be stored at -20 ◦C or -80◦ C for later analyses, or analyzed at once (Hb, leukocytes, thrombocytes, CRP, electrolytes, liver enzymes, lipids, bleeding status, glomerular filtration rate (GFR), insulin, fp-glucose, HbA1c and thyroid-stimulating hormone (TSH), cobalamin, folate and routine urine analyses incl microalbuminuria).
The questionnaires 1, 3, 4, and 5, and experimental procedures will be repeated after 3 months of the diet and at termination after 6 months, with standard food the last 3 months.
Two weeks after introduction of the new diet, insulin, glucose and proinsulin are measured in plasma/serum, along with anthropometric protocol.
During the evaluation of the diet, the subjects have to continue with the same degree of physical activity as previously. No dietary supplements such as fish oil, probiotics or multivitamin drugs are allowed to take. As most one visit to a restaurant or to another diet per week is allowed. Journeys or a stay during a longer time period at another place must be discussed with the leader of the research. Maximal intake of alcoholic beverages is 30 g ethanol/week. 12 g ethanol corresponds to the following: 1 bottle (50cl) ordinary beer, 1 bottle (33cl) strong beer, 1 glass (15cl) wine, 1 glass (8cl) strong wine, or 1 glass (4cl) spirits. formula: volume% x ml volume/100 x 0.8.
Test meal in a substudy of healthy volunteers
The subjects come fasting (12 h) in the morning, bringing the breakfast to consume. Before starting the meal, two blood samples are taken with 10 min in between. After the start of the meal, a new blood sample is collected at 10, 20, 30, 45, 60, 90, 120, and 180 min afterwards. Each blood sample consists of 6 ml plasma. At the same time intervals, the satiety score is completed. With a few days in between, the same procedure is performed where their previous ordinary, daily breakfast is replaced by the new diet, so that 2 test meals are performed during run-in; one with ordinary breakfast and one with new diet breakfast.
During the whole study, PI has a close contact (email and phone) with the patient to be able to support the patient and enhance compliance as much as possible.
- Conditions
- Obesity, Diet Modification
- Being tested
- low carbohydrate food, standard food
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
low carbohydrate foodDietary supplement
low carbohydrate food
standard foodDietary supplement
standard food
| Study group | Role | What they receive |
|---|---|---|
| low carbohydrate food | Experimental | The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.
Intervention: Food: Low carbohydrate food Receives: Dietary Supplement: low carbohydrate food |
| standard food | Active comparator | The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food Receives: Dietary Supplement: standard food |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in metabolic effects, intestinal permeability and microbiota composition after food intervention
In the larger study, the investigator will give the patients a moderate, low carbohydrate food for 3 months and then evaluate the effects in plasma concentration of insulin, fp-glucose, C-peptide, proinsulin, HbA1c, lipids, and zonulin. Feces wil be analyzed for microbiota composition as quantified by PCR.
Measured: 3 months
Secondary outcomes (1)
Quality of life as assessed by the SF-36
In the larger study, the investigator will give the patients a moderate, low carbohydrate food for 3 months and assess the quality of life before and after intervention by SF-36
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2015 (estimated)
- Study startNov 2014
- Primary completion15 Oct 2015
- Study completion31 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Region SkaneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University
- Responsible party
- Principal investigator, Bodil Ohlsson, Region Skane
- Investigators
- Bodil Ohlsson, Professor, Principal investigator, Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02405806
- Sponsor's protocol ID
- 140917-281
- Status last verified
- Jan 2018
- First submitted
- 23 Feb 2015
- Last updated
- 10 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Ohlsson B, Bjorgell O, Ekberg O, Darwiche G. The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a semisolid meal compared to saline in human. BMC Gastroenterol. 2006 Mar 16;6:11. doi: 10.1186/1471-230X-6-11.
PubMed 16542457Sullivan M, Karlsson J, Taft C. SF-36: Swedish manual and interpretation guide, 2nd Edition. Gothenburg: Sahlgrenska University Hospital. 2002.
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms
- ClinicalTrials.gov ID
- NCT02405806
- Acronym / sponsor ID
- 140917-281
- Conditions
- Obesity, Diet Modification
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Lund University
- Study start
- Nov 2014
- Primary completion
- 15 Oct 2015 (actual)
- Study completion
- 31 Dec 2017 (actual)
- First posted
- 1 Apr 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall aim for this study is to evaluate the clinical effects of a modified diet on metabolic risk factors such as diabetes mellitus and obesity, and the mechanisms this nutrition composition exerts on gastrointestinal physiology, inflammatory responses, and quality of life, where the subjects are their own controls.
Within this study, the investigators will be able to relate the nutritional composition to metabolic disorders, the gut microbiota, secreted intestinal neuropeptides, and bio- and inflammatory markers in serum, plasma and urine.
Detailed description
Material and Methods
Subjects are recruited consequently from the primary care, and from the Department of Endocrinology.
Study population
The investigator will include:
- patients with type 2 diabetes to study the effect of a modified diet for 3 months;
- healthy volunteers for intake of two different breakfasts with some days in between the meals.
All categories will be exposed to exactly the same study design.
Protocols:
Various protocols will be used in the study, to collect information about the status at inclusion, and to be able to measure changes in anthropometry, health status and symptoms during the study period.
Study-questionnaire:
This questionnaire is similar to the questionnaires used in the great population cohorts Malmö Diet and Cancer Study (MDCS, general population from Malmö, N = 28 000), and Malmö Offspring Study (MOS) (general population from Malmö, children and grandchildren to participants in MDCS, calculated to include 5000 participants, started 2013, supported by grants from VR). It is also used in a newly started endoscopy study where all consecutive patients performing a colonoscopy at the Department of Gastroenterology in Malmö will be included (calculated to include 2000 participants). The questionnaire contains questions about socioeconomic factors, life style factors (including diet, smoking, stuff use, alcohol habits, physical activity), medical health, drug consumption, heredity factors and gastrointestinal symptoms.
Nutrition questionnaire:
This questionnaire is used to get information about ordinary diet, energy intake, and so on. This basic information is used to plan the diet from Life Science Lab, so similar energy supply and breakfast are provided.
36-item Short-Form questionnaire (SF-36): This is a world-wide used instrument to evaluate quality of life. It has been used to measure quality of life in many various diseases, and norm value references are available. The instrument measures physical functioning, role functional-physical, bodily pain, general health, vitality, social functioning, role functioning-emotional, and mental health. These parameters are valuable to evaluate, to estimate the effects evoked in daily life, by a change in life style factors.
Anthropometric protocol:
This questionnaire is used to screen the study participants before inclusion, and to be able to exclude patients with already ongoing weight-reducing diet. In addition, it contains questions about BMI, body composition, and a basal physical examination.
Satiety scoring:
This protocol has been used in previous studies by the group, to estimate the degree of hunger/satiety before and after a standardized meal.
Nutrition:
All subjects will get the diet delivered free from charge from Life Science Lab (Lund University). Life Science Lab was founded 1998 as a leading medical and technical research for advanced cardiovascular and thoracic surgery sciences. Due to the importance of life style effects on the cardiovascular diseases and well-being, Life Science Lab also conducts life style-related science to reduce known risk factors for cardiovascular diseases. The main focus is to develop healthy nutrition in normal food formula by reforming the food-meal composition for everyone. The meal-diet consists of ordinary raws, but with minimal industrial processing. The food is based on traditional Nordic raws, e.g. whole grains, vegetables, leguminous, root crops, fat fish, birds, fruits, berries and nuts. At the same time, the amount of sugar, read meat, processed meat, and dairy products is limited. The diet has a good nutritional supply, but contains less calories than what is usually recommended (2000 kcal/day compared with 2400 kcal/day).
The meal is planned together with the kitchen of Life science Lab. Food composition, recipes, and instructions how to cook the food is delivered regularly from Life Science Lab for lunch and dinner. The breakfasts for the subjects are planned together with the PI and the nutritionist at Life Science Lab, but the subjects have to buy the food themselves. Three alternatives are suggested, depending on their ordinary breakfast ingested, described in the nutrition questionnaire.
Neuropeptides/inflammatory markers:
The neuropeptides, or their precursors, that will be studied in serum/plasma are peptides involved in regulation of satiety and digestion, e.g. cholecystokinin (CCK), gastrin, ghrelin, glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2), leptin, motilin, neurotensin, oxytocin, and peptide YY (PYY). To evaluate permeability defects in the intestinal mucosa, levels of zonulin and bacterial endotoxins, i.e. lipopolysaccharides, will be measured in plasma. Low-graded inflammation is reflected by high-sensitive C-reactive protein (CRP), plasminogen activator inhibitor type 1 (PAI-1), and factors involved in AGE will be analyzed. In addition, different cytokines, tracers, and routine analyses will be performed. Cooperation with laboratories in Denmark and Great Britain will be established.
Gut microbiota:
DNA extractions and Terminal Restriction Fragment Length Polymorphism (T-RFLP) and quantification of specific bacterial groups will be done by quantitative polymerase chain reaction (PCR) in accordance with the protocols the investigator has used and described earlier by the research group. As reference, a restricted number of samples will be analyzed with massively-parallel pyrosequencing of partial ribosomal ribonucleic acid (rRNA) ribosomal genes. The gut microbiota bacterial constitution (bacterial species) will be correlated to gastrointestinal symptoms and diseases, and changes in bio- and inflammatory markers.
Study Design
When a group of patients are recruited, the investigator will have an information meeting for the whole group. At that meeting, held by the PI, the subjects will receive medical information about metabolic diseases, and about nutrition and its effects on health and disease.
After this initial meeting, the subjects are handled individually. For overview, se flow-chart, last page. At inclusion, all subjects have to complete questionnaires and some examinations:
- Study-questionnaire containing questions about ordinary lifestyle factors, socioeconomic factors, health- and drug information, heredity, and gastrointestinal symptoms;
- Nutrition questionnaire containing information about ordinary food habits
- Quality of life questionnaire SF-36;
- Anthropometric protocol, including nutritional screening, completed by the investigator; and
- Eight tubes (SST- phenolsulfotransferase platelet survival time (PST)- and ethylenediaminetetraacetic acid (EDTA) tubes), à 6 ml, to collect serum, plasma and blood cells. Feces sampling for microbiota analyses. Urine sampling during the night. All biological material will be stored at -20 ◦C or -80◦ C for later analyses, or analyzed at once (Hb, leukocytes, thrombocytes, CRP, electrolytes, liver enzymes, lipids, bleeding status, glomerular filtration rate (GFR), insulin, fp-glucose, HbA1c and thyroid-stimulating hormone (TSH), cobalamin, folate and routine urine analyses incl microalbuminuria).
The questionnaires 1, 3, 4, and 5, and experimental procedures will be repeated after 3 months of the diet and at termination after 6 months, with standard food the last 3 months.
Two weeks after introduction of the new diet, insulin, glucose and proinsulin are measured in plasma/serum, along with anthropometric protocol.
During the evaluation of the diet, the subjects have to continue with the same degree of physical activity as previously. No dietary supplements such as fish oil, probiotics or multivitamin drugs are allowed to take. As most one visit to a restaurant or to another diet per week is allowed. Journeys or a stay during a longer time period at another place must be discussed with the leader of the research. Maximal intake of alcoholic beverages is 30 g ethanol/week. 12 g ethanol corresponds to the following: 1 bottle (50cl) ordinary beer, 1 bottle (33cl) strong beer, 1 glass (15cl) wine, 1 glass (8cl) strong wine, or 1 glass (4cl) spirits. formula: volume% x ml volume/100 x 0.8.
Test meal in a substudy of healthy volunteers
The subjects come fasting (12 h) in the morning, bringing the breakfast to consume. Before starting the meal, two blood samples are taken with 10 min in between. After the start of the meal, a new blood sample is collected at 10, 20, 30, 45, 60, 90, 120, and 180 min afterwards. Each blood sample consists of 6 ml plasma. At the same time intervals, the satiety score is completed. With a few days in between, the same procedure is performed where their previous ordinary, daily breakfast is replaced by the new diet, so that 2 test meals are performed during run-in; one with ordinary breakfast and one with new diet breakfast.
During the whole study, PI has a close contact (email and phone) with the patient to be able to support the patient and enhance compliance as much as possible.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| low carbohydrate food | Experimental | Dietary Supplement: low carbohydrate foodThe subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously. Intervention: Food: Low carbohydrate food |
| standard food | Active comparator | Dietary Supplement: standard foodThe subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy subjects should be healthy.
- Prediabetes should have fasting plasma glucose levels o 5.6-6.9 mmol/l or plasma glucose level 2 h after an oral glucose test of 7.8-11.1 mmol/l, without any diabetes treatment.
- Patients with diabetes should have type-2 diabetes.
- Obesity should have BMI 30-3 and glucose levels within reference values
Key exclusion criteria (1 listed)
- Patients with diabetes or obesity should not have severe cardiac, kidney, liver or psychiatric diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| low carbohydrate foodlow carbohydrate food | Dietary supplement | low carbohydrate food |
| standard foodstandard food | Dietary supplement | standard food |
Primary outcome
Change from baseline in metabolic effects, intestinal permeability and microbiota composition after food intervention
Time frame: 3 months
In the larger study, the investigator will give the patients a moderate, low carbohydrate food for 3 months and then evaluate the effects in plasma concentration of insulin, fp-glucose, C-peptide, proinsulin, HbA1c, lipids, and zonulin. Feces wil be analyzed for microbiota composition as quantified by PCR.
1 secondary outcome
Quality of life as assessed by the SF-36
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2018.
- Background: PubMed 16542457Ohlsson B, Bjorgell O, Ekberg O, Darwiche G. The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a semisolid meal compared to saline in human. BMC Gastroenterol. 2006 Mar 16;6:11. doi: 10.1186/1471-230X-6-11.
- BackgroundSullivan M, Karlsson J, Taft C. SF-36: Swedish manual and interpretation guide, 2nd Edition. Gothenburg: Sahlgrenska University Hospital. 2002.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bodil Ohlsson, Professor principal investigator
Lund University
Questions about this trial
What is this clinical trial studying?
A study testing low carbohydrate food and standard food in people with Obesity and Diet Modification, run by Region Skane.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in metabolic effects, intestinal permeability and microbiota composition after food intervention (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02405806, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2018.